Loading...
Market
What will be Revuforj's market share rank among menin inhibitors by 2025 end?
2
Resolution / Starting Odds
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
Market analysis reports from reputable research firms
Story
FDA Approves Syndax's Revuforj for Acute Leukemia, Shares Rise 4%
Nov 15, 2024, 10:53 PM
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), developed by Syndax Pharmaceuticals, for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation. This approval, announced on Friday, is significant as Revuforj is the first and only menin inhibitor to treat this specific type of leukemia. The drug is approved for both adult and pediatric patients one year and older. Following the announcement, Syndax Pharmaceuticals' shares rose by 4% in after-hours trading.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Below Top 30 • 25%